Table 1.
Demographic Characteristics of the Study Subjects According to Quartiles of Total BCAAs
| Characteristics | Q1 (81) | Q2 (80) | Q3 (82) | Q4 (79) | P-value |
|---|---|---|---|---|---|
| Age (year)* | 70(67, 76) | 68(65, 75) | 68(65, 72) | 67(64, 71) | 0.001 |
| Height (cm) | 157.3 ± 8.5 | 158.5 ± 8.1 | 160.0 ± 7.7 | 162.7 ± 8.8 | <0.001 |
| Weight (kg) | 62.85 ± 10.3 | 63.4 ± 11.5 | 65.6 ± 10.4 | 70.0 ± 11.4 | <0.001 |
| Urine volume (mL)* | 800(625, 1050) | 950(662, 1400) | 1194(800, 1620) | 1400(1000, 1900) | <0.001 |
| Gender (female) | 46 (56.8%) | 50 (62.5%) | 34 (41.5%) | 30 (38.0%) | 0.004 |
| Smoking history | 16 (19.8%) | 17 (21.3%) | 24 (29.3%) | 22 (27.8%) | 0.403 |
| Current smoking habit | 7 (8.6%) | 8 (10.0%) | 13 (15.9%) | 11 (13.9%) | 0.462 |
| Education (primary) | 79 (97.5%) | 78 (97.5%) | 75 (91.5%) | 72 (91.1%) | 0.101 |
| Drugs History | |||||
| Diuretics | 14 (17.3%) | 12 (15.0%) | 14 (17.1%) | 9 (11.4%) | 0.709 |
| ACEI | 26 (32.1%) | 29 (36.3%) | 30 (36.6%) | 31 (39.2%) | 0.823 |
| α-receptor blockers | 5 (6.2%) | 2 (2.5%) | 3 (3.7%) | 4 (5.1%) | 0.673 |
| β-receptor blockers | 7 (8.6%) | 9 (11.3%) | 10 (12.2%) | 13 (16.5%) | 0.499 |
| Calcium antagonists | 42 (51.9%) | 45 (56.3%) | 50 (61.0%) | 52 (65.8%) | 0.309 |
| Other antihypertensives | 16 (19.8%) | 11 (13.8%) | 11 (13.4%) | 9 (11.4%) | 0.472 |
| Lipid-lowering drugs | 7 (8.6%) | 3 (3.8%) | 4 (4.9%) | 3 (3.8%) | 0.461 |
| Antiplatelet agents | 24 (29.6%) | 20 (25.0%) | 22 (26.8%) | 18 (22.8%) | 0.790 |
Note: * Values shown are Median (P25, P75).
Abbreviations: ACEI, angiotensin conversion enzyme inhibitors; total BCAAs, valine + isoleucine + leucine; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.